伊奥尼斯制药 IONS 深 沪
等待开盘 02-05 09:30:00 美东时间
84.99
+0.400
+0.47%
华盛通- 最 高85.95
- 今 开85.72
- 成交量 301.00万股
- 最 低 82.545
- 昨 收 84.59
- 总市值 137.68亿
- 52周最高 86.15
- 市盈率 静 --
- 换手率 1.86%
- 52周最低 23.95
- 委 比 -41.18%
- 总股本 1.62亿
- 历史最高 86.582
- 量 比 1.65
- 振 幅 4.03%
- 历史最低 6.25
- 每 手 1
- 风险率 19.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ionis Pharmaceuticals EVP Eric Swayze Reports Sale of Common Shares
Ionis Pharmaceuticals EVP Eric Swayze Reports Sale of Common Shares Eric Swayze, Executive Vice President of Research at Ionis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by
02-03 09:52
Ionis Pharmaceuticals EVP CLO & General Counsel Patrick R. O'Neil Reports Disposal of Common Shares
Ionis Pharmaceuticals EVP CLO & General Counsel Patrick R. O'Neil Reports Disposal of Common Shares Patrick R. O’Neil, EVP CLO & General Counsel of Ionis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: Thi
02-03 09:52
Ionis Pharmaceuticals CEO Brett P. Monia Reports Disposal of Common Shares
Ionis Pharmaceuticals CEO Brett P. Monia Reports Disposal of Common Shares Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was
02-03 09:52
Ionis Pharmaceuticals EVP Brian Birchler Reports Sale of Common Shares
Ionis Pharmaceuticals EVP Brian Birchler Reports Sale of Common Shares Brian Birchler, EVP, Corp and Development Ops of Ionis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by
02-03 09:52
Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Disposal of Common Shares
Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Disposal of Common Shares Frank C. Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals Inc., reported a disposal of common shares of Ionis Pharmaceuticals Inc. The full filing can be accessed through the link
02-03 09:51
Ionis Pharmaceuticals EVP Chief Business Officer Joseph Baroldi Reports Sale of Common Shares
Ionis Pharmaceuticals EVP Chief Business Officer Joseph Baroldi Reports Sale of Common Shares Joseph Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This ne
02-03 09:51
The European Commission Approves Ionis Pharmaceuticals' And Otsuka Pharmaceutical's Dawnzera (Donidalorsen) For Routine Prevention Of Recurrent Attacks Of Hereditary Angioedema In Patients Aged 12 Years And Older
The approval is based on positive results from the Phase 3 OASIS-HAE and OASISplus studies, in which DAWNZERA demonstrated positive results across multiple measures of disease including significant and sustained
01-21 20:05
BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)
BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae) Jan 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O : DAWNZERA™ (DONIDALORSEN) APPROVED IN THE EUROPEAN UNION FOR HEREDITARY ANGIOEDEMA (HAE) IONIS PHARMACEUTICALS INC - ELIGIBLE FOR MILESTONE PAYMENT OF $1
01-21 20:04
EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention
EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention Ionis Pharmaceuticals Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has approved DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE)
01-21 20:00
Ionis Pharmaceuticals EVP Eugene Schneider Reports Sale of Common Shares
Ionis Pharmaceuticals EVP Eugene Schneider Reports Sale of Common Shares Eugene Schneider, Executive Vice President and Chief Clinical Development Officer of Ionis Pharmaceuticals Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. D
01-21 09:22
